GRTS Gritstone Oncology

Gritstone Oncology to Present at Two Upcoming Investor Conferences in August

Gritstone Oncology to Present at Two Upcoming Investor Conferences in August

EMERYVILLE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced presentations at two upcoming investor conferences in August.

  • Karin Jooss, Ph.D., executive vice president of research and chief scientific officer, will present at the William Blair Biotech Focus Conference 2020 on Wednesday, August 5, 2020 at 2:25 p.m. ET.
  • Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present at the BTIG Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 2:00 p.m. ET.

A live webcast will be available within the Investors & Media section of the Gritstone Oncology website at . An archived replay will be accessible for 30 days following the event.

About Gritstone Oncology

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—second, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to potentially drive the patient’s immune system to specifically attack and destroy tumors. The company’s individualized neoantigen-based immunotherapy, GRANITE, and its “off the shelf” shared neoantigen-based immunotherapy, SLATE, are being evaluated in clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone’s BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.

Contacts

Media:

Dan Budwick

1AB

(973) 271-6085

Investors:

Alexandra Santos

Wheelhouse Life Science Advisors

(510) 871-6161

EN
03/08/2020

Underlying

GRTSGritstone Oncology

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Gritstone Oncology

 PRESS RELEASE
Free
GRTS Gritstone Oncol...

Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for...

Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update -- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.50 [90% CI, 0.20-1.28]) -- -- Progressing through court-administered financial restructuring process with continued interest from multiple parties  EMERYVILLE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (O...

November 11, 2024 1 EN
 PRESS RELEASE
Free
GRTS Gritstone Oncol...

Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualize...

Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer --Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.79 [95% CI, 0.42-1.50])-- -- 38% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA s...

September 30, 2024 1 EN
 PRESS RELEASE
Free
GRTS Gritstone Oncol...

Gritstone bio Reports Second Quarter 2024 Financial Results and Provid...

Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates -- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer -- -- Presentations at AACR 2024 and ESCMID Global 2024 demonstrate the broad...

August 13, 2024 1 EN
 PRESS RELEASE
Free
GRTS Gritstone Oncol...

Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Pote...

Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) -- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced it will host a virtual key opinion leader (KOL) event on Friday, Aug...

July 24, 2024 1 EN
 PRESS RELEASE
Free
GRTS Gritstone Oncol...

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 56...

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EMERYVILLE, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 39,000 shares of its common stock with an exercise price of $0.57, which is equal to the closing price of Gritstone’s common stock on July 3, 2024, the date of the grant. T...

July 10, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch